JPRN-jRCTs051180077已完成4 期
Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients. - Clot regression in cancer VTE patients
Matoba Satoaki0 个研究点目标入组 40 人开始时间: 2019年2月27日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
This study revealed that rivaroxaban had a sufficient clot-regression effect for the treatment of VTE in cancer patients. It exhibited an acceptable safety profile; however, future clinical use in patients with gastrointestinal or genitourinary cancers should be met with caution.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •1) Patients with active cancer* at diagnosis with VTE (symptomatic or asymptomatic)
- •2) Untreated VTE
- •3) Patients aged 20 to 75 years
- •4) Patient signed the imformed consent to participate in this study
- •*Active cancer at baseline was defined as a diagnosis of cancer that occurred within 6 months before enrollment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer
排除标准
- •1) Patients contraindicated for rivaroxaban
- •2) Rivaroxaban therapy within 30 days before informed consent
- •3) Fibrinolytic therapy within 30 days before informed consent
- •4) Creatinine clearance <30 mL/min
- •5) Life expectancy <6 months
- •6) Isolated distal DVT
- •7) Treatment with vitamin K antagonist
- •8) Severe complication (significant liver disease, active bleeding or a high risk of bleeding contraindicating anticoagulant treatment, severe hypertension (a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg))
- •9) Pregnancy, and breast-feeding
- •10) Individuals who are scheduled to participate in other interventional study during this study
- •11) Surgical operation is scheduled during this study
- •12) Contraindicated for contrast agent/ Allergic reaction to contrast agent
- •13) Patients who the physician in charge judges ineligible for the present study
研究者
相似试验
已完成
不适用
Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients.Venous thromboembolismJPRN-UMIN000027793Kyoto Prefectural University of Medicine40
已完成
2 期
Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee ArthroscopyHaemorrhageVenous ThromboembolismNCT01629381University of Padova500
已完成
不适用
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)Treatment of Venous Thromboembolism in Cancer PatientsCancerVenous ThromboembolismNCT05461807Bayer2,437
已完成
不适用
A Prospective Pharmacodynamic Study of RivaroxabanBlood ClotNCT01743898University of North Carolina, Chapel Hill65
已完成
3 期
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill PatientsVenous ThromboembolismNCT00571649Bayer8,101